Yoichi Ozawa
Tsukuba, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Correction: Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium.
Journal: Cancer research communications
Published: November 06, 2025
Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine.
Journal: Cancer research communications
Published: August 06, 2024
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium.
Journal: Cancer research communications
Published: April 09, 2024
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody.
Journal: Molecular cancer therapeutics
Published: July 15, 2022
Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Journal: Cancer research
Published: July 18, 2020
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Journal: Cancer research
Published: March 09, 2020
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Journal: PloS one
Published: October 11, 2018
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Journal: Anticancer research
Published: September 06, 2017
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Journal: Cancer science
Published: September 22, 2016
Synthesis and structure-activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors.
Journal: Bioorganic & medicinal chemistry
Published: June 02, 2014
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Journal: Cancer science
Published: March 12, 2014
Last Updated: 09/26/2026